Oncology

A new partnership arms independent cancer clinics with advanced AI and data analytics, aiming to improve patient care and ensure their survival.

The firm is now recruiting for a Phase 1 trial of HWK-007 and has submitted an IND for HWK-016, targeting tough lung, ovarian, and endometrial cancers.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

A new partnership aims to bring cutting-edge cancer trials to community clinics, accelerating drug development and expanding patient access to care.

858 Therapeutics' novel PARG inhibitor offers new hope for patients with a deadly, drug-resistant form of ovarian cancer, accelerating its path to approval.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

A newly validated genetic test accurately predicts melanoma risk, offering a non-invasive alternative to the standard surgical biopsy for many patients.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

A new partnership aims to use advanced nuclear reactors to produce life-saving medical isotopes on U.S. soil, tackling a critical national vulnerability.

With a massive $200M Series C, Soley Therapeutics is using its AI cell-sensing platform to fast-track novel cancer drugs from code to clinic.

Australian CRO Avance Clinical buys U.S. specialist LumaBridge, creating a global center of excellence to accelerate cancer therapies for biotech firms.

A new multi-target deal combines cutting-edge platforms to create next-gen cancer drugs, aiming to improve precision and patient outcomes.

With its first drug approved and a deep pipeline, all eyes are on Nuvation Bio's CEO David Hung at the upcoming J.P. Morgan Healthcare Conference.

A landmark trial reveals a new drug combination from BeOne Medicines extends life significantly in advanced stomach cancer, poised to become the new standard.

With its lead asset TEC-001 targeting tough liver cancers, Teclison's presence at the ASCO GI Symposium puts its innovative approach in the spotlight.

With its massive data library and AI platforms, Tempus AI prepares for a pivotal presentation. What will CEO Eric Lefkofsky reveal to investors?

Newcomer Candid Therapeutics is set to unveil its T-cell engager platform at J.P. Morgan, a move that could shake up the autoimmune treatment landscape.

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.

Inspira Technologies announces a landmark deal to acquire a liquid biopsy firm, securing a $15M investment at a $180M valuation to enter the cancer market.